LONDON (The Deal) -- European stock indices rallied and Asian markets were mixed Thursday after the Federal Reserve said it would pare back its $85 billion monthly bond buying program by $10 billion starting in January and made reassuring comments about the outlook for interest rates.
The central bank said it doesn't foresee rates moving much beyond zero until well past the time unemployment in the U.S. falls below 6.5%.
In London, the FTSE was up 0.92% at 6,551.93. U.K. retail sales data for November confirmed a picture of increasing consumer confidence after an October blip. Sales expanded 2% year-on-year, and were up 0.3% in the month, in line with forecasts.
In Frankfurt, the DAX jumped 1.37% to 9,307.91, and in Paris the CAC was up 1.49% at 4,170.83.
In London, AstraZeneca
(AZN) rose after it announced plans to spend up to $4.3 billion buying out partner Bristol-Myers Squibb
(BMY) from a diabetes joint venture. Diabetes is becoming a major problem in many fast-growing emerging-markets where AstraZeneca is already present and the London company wants to tap into that demand.
In Germany, drugmaker Bayer also announced a deal with a partner, Algeta of Norway. It agreed to pay 17.6 billion Norwegian kroner ($2.9 billion) to take over the company, with whom it collaborates on the Xofigo prostrate cancer drug. The offer represents an improvement from an early November proposal from Bayer, which some analysts said at the time already looked pricey. But shares in both companies rose, with Algeta trading just below the Nkr362 per share offer price.
In Tokyo, the Nikkei rose 1.74% to 15,859.22 as the falling yen, which touched a five-year low against the dollar, aided exporters. The Nikkei is at a six-year high. In Hong Kong, the Hang Seng fell 1.1% to 22,888.75. Mainland Chinese indices also fell on concerns that a change of government policy will push up financing costs.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts